

,QÀL[LPDE ELRVLPLODUV 5HPVLPDØ LQ WKHUDS\ RI ,%' SDWLHQ

Background: e evidence on e cacy and safety of biosimilars in iximab (IFX) in patients with in ammatory bowel diseases

Notes: